Here are relevant reports on : dna-sequencing-market
-
Europe Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Service, Application (Drug Discovery, Diagnostic, Agriculture)-Forecast to 2030
The Europe Next-generation Sequencing Market, valued at US$4.11 billion in 2024, stood at US$4.42 billion in 2025 and is projected to advance at a resilient CAGR of 15.0% from 2025 to 2030, culminating in a forecasted valuation of US$8.88 billion by the end of the period. The Europe next-generation sequencing market is expanding on the back of accelerating use of sequencing across oncology, rare disease diagnostics, and broader precision medicine programs, supported by robust public and private research funding
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Service, Application (Drug Discovery, Diagnostic, Agriculture) - Global Forecast to 2030
The next-generation sequencing market, valued at US$13.95 billion in 2024, stood at US$14.94 billion in 2025 and is projected to advance at a resilient CAGR of 14.6% from 2025 to 2030, culminating in a forecasted valuation of US$29.53 billion by the end of the period. The next-generation sequencing (NGS) market continues to grow steadily. A key driver of this expansion is the clinical adoption of NGS across oncology, rare diseases, reproductive health, and infectious diseases. This trend is also accompanied by lower cost per genome and the launch of higher-throughput benchtop and clinical instruments.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Global DNA and Gene Chip (Microarrays) Market (2010 – 2015)
The Global DNA & Gene Chip (microarray) market was valued at $760 million in 2010 and is expected to reach $1,425.2 million by 2015 growing at a CAGR of and 13.4%. The oDNA segment accounted for the largest share – 98% – of the global DNA & gene chip market in 2010.
- Published: May 2011
- Price: $ 4950
- TOC Available:
-
Biochips Market by Products & Services (Instruments, Software), Type (DNA Chips, Protein Chips, Lab-on-a-Chip), Application (High-throughput Screening, IVD, POC), Fabrication Technology (Microarrays, Microfluidics), & Region - Global Forecast to 2030
The global biochips market, valued at US$12,907.5 million in 2024, stood at US$14,011.6 million in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2024 to 2030, culminating in a forecasted valuation of US$21,356.4 million by the end of the period.
- Published: November 2025
- Price: $ 4950
- TOC Available:
-
Epigenetics Market by Product & Service (Enzymes, Kits & Reagents (Antibodies), Software), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR), Application (Oncology, Immunology, Developmental Biology), End User - Global Forecast to 2030
The global epigenetics market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025 and is projected to advance at a resilient CAGR of 11.3% from 2025 to 2030, culminating in a forecasted valuation of US$4.29 billion by the end of the period. The major factors driving the growth in epigenetics market includes reduced sequencing costs and accelerated turnaround times to improve access and affordability of epigenetic analysis.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) - Global Forecast to 2026
The global aptamers market growth is primed to transition from $151 million in 2021 to $342 million by 2026, showcasing a strong CAGR of 17.7%. Growth of the market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
Apoptosis Assays Market by Product (Caspase, Annexin V, DNA Fragmentation, Mitochondrial Assay), Detection Technology (Flow Cytometry, Florescence microscopy), Application (Stem Cell, Discovery & Development, Clinical Research) & Region - Global Forecasts to 2023
The global apoptosis assays market is projected to reach USD 5.9 billion by 2023, at a CAGR of 10.5%. The prominent players in the apoptosis assays market are Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US), Sartorius AG (Germany), Danaher Corporation (US), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US).
- Published: November 2018
- Price: $ 4950
- TOC Available:
-
North America Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology]-Forecast to 2030
The North America epigenetics market, valued at USD 0.84 billion in 2024, stood at USD 0.93 billion in 2025 and is projected to advance at a resilient CAGR of 13.8% from 2025 to 2030, culminating in a forecasted valuation of USD 1.78 billion by the end of the period. Growth of the North America epigenetics market is driven by a strong, well-funded life sciences ecosystem, with rising oncology and precision-medicine programs that rely on methylation and chromatin profiling.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Microarray Analysis Market by Product & Service (Consumables, Instrument, Software, Services), Type (DNA, Protein Microarray), Application (Research), End User (Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies) - Global Forecasts to 2023
The global microarray analysis market is projected to reach USD 5.52 billion by 2023, at a CAGR of 7.6%. The major factors driving the growth of this market are the increasing incidence of cancer, increasing funding for genomic and proteomic research, and growing application areas of microarrays. Key players in the microarray analysis market include Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Molecular Devices (US), PerkinElmer Inc. (US), Illumina, Inc. (US), GE Healthcare (US), and Bio-Rad Laboratories Inc. (US).
- Published: August 2018
- Price: $ 4950
- TOC Available:
-
NGS Sample Preparation Market by Product (Reagents & Consumables, Workstations), Workflow (Library Prep, Target Enrichment), Sample Type (DNA), Application (Diagnostics, Drug Discovery), Method (Microfluidic, Automated), End User & Region - Global Forecast to 2028
The global NGS sample preparation market in terms of revenue was estimated to be worth $1.9 billion in 2022 and is poised to reach $4.0 billion by 2028, growing at a CAGR of 13.4% from 2022 to 2028. The market for NGS sample preparation is highly consolidated, with key players strategizing to capture the market. Prominent players in the NGS sample preparation market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), PerkinElmer Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Danaher (US), Becton, Dickinson and Company (US), Merck KGAA (Germany), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Eurofins Scientific (Luxembourg), BGI (China), 10x Genomics (US), Sysmex Corporation (US), Psomagen (US), Zymo Research Corporation (US), Takara Bio Inc. (Japan), Novogene Co., Ltd. (China), New England Biolabs (US), Tecan Trading AG (US), Oxford Nanopore Technologies PLC (UK), PacBio (US), Medgenome (US), and Swift Biosciences Inc. (US).
- Published: March 2023
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
